IP Library Granted Patent US 12,697,318
Granted Patent B2
US 12,697,318 · App. 16/953,129 · Granted Aug 4, 2026

Anti-inflammatory agent containing rare fatty acid

Inventors: Jun Ogawa (Kyoto, JP); Shigenobu Kishino (Kyoto, JP); Teruo Kawada (Kyoto, JP); Nobuyuki Takahashi (Kyoto, JP); Tsuyoshi Goto (Kyoto, JP); Tatsuya Sugawara (Kyoto, JP); Yasunori Yonejima (Muko, JP)
Assignee: Noster Inc.
A61K31/20A23L33/12A61K31/201A61K31/202A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,318
App. No.
16/953,129
Filed
Nov 19, 2020
Granted
Aug 4, 2026
Kind
B2
Art Unit
1622
USPC
514/560
Abstract

The present invention provides an anti-inflammatory agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the anti-inflammatory agent.

Claims (3)

1 . A method for inducing differentiation of macrophage into M2 macrophage, comprising administering to a patient an effective amount of a fatty acid, wherein the fatty acid is 13-hydroxy-cis-9, cis-15-octadecadienoic acid or 13-oxo-cis-6, cis-9-octadecadienoic acid.

2 . The method according to claim 1 , wherein the fatty acid is 13-hydroxy-cis-9,cis-15-octadecadienoic acid.

3 . The method according to claim 1 , wherein the fatty acid is 13-oxo-cis-6,cis-9-octadecadienoic acid.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTY TYPE FROM APPLICATION NUMBER TO PATENT NUMBER FOR 10952983 AND 10975397 PREVIOUSLY RECORDED AT REEL: 68851 FRAME: 663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 069207/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2024
From: OGAWA, JUN; KISHINO, SHIGENOBU; KAWADA, TERUO; TAKAHASHI, NOBUYUKI; GOTO, TSUYOSHI; SUGAWARA, TATSUYA; YONEJIMA, YASUNORI
To: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 068943/0015 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 068851/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055920/0263 →
Priority Claims (2)
JP 2014-011866 · Jan 24, 2014 · national
JP 2014-162982 · Aug 8, 2014 · national
Continuity (2)
Division 15113714 · Jan 23, 2015
Related Publication 20210069141A1 · Mar 11, 2021
References Cited (69)
US 4908384A · Ho · 1990 [cited by examiner]
US 5260336A · Forse · 1993 [cited by examiner]
US 9707200B2 · Ogawa et al. · 2017 [cited by applicant]
US 20050214241A1 · Kandil · 2005 [cited by examiner]
US 20100035989A1 · Schwartz et al. · 2010 [cited by applicant]
US 20110190389A1 · Arterburn · 2011 [cited by examiner]
US 20120142773A1 · Kelliher et al. · 2012 [cited by applicant]
US 20130274327A1 · Arita et al. · 2013 [cited by applicant]
US 20150125911A1 · Ogawa et al. · 2015 [cited by applicant]
US 20150342916A1 · Ogawa et al. · 2015 [cited by applicant]
US 20160000739A1 · Ogawa et al. · 2016 [cited by applicant]
US 20170000752A1 · Ogawa et al. · 2017 [cited by applicant]
CN 101611894A · 2009 [cited by examiner]
CN 102458391A · 2012 [cited by applicant]
JP 3103274B2 · 2000 [cited by examiner]
JP 2003073329A · 2003 [cited by examiner]
JP 2005008594A · 2005 [cited by applicant]
JP 2009051732A · 2009 [cited by applicant]
JP 2009545527A · 2009 [cited by applicant]
JP 2011184411A · 2011 [cited by applicant]
KR 100793081B1 · 2008 [cited by examiner]
KR 101281470B1 · 2013 [cited by examiner]
WO WO9310776A1 · 1993 [cited by examiner]
WO WO9600584A1 · 1996 [cited by examiner]
WO WO1999016435A1 · 1999 [cited by applicant]
WO WO2004002234A1 · 2004 [cited by examiner]
WO WO2004084829A2 · 2004 [cited by examiner]
WO WO2007069758A1 · 2007 [cited by examiner]
WO WO2012023254A1 · 2012 [cited by applicant]
WO WO2013003689A2 · 2013 [cited by examiner]
WO WO2013168310A1 · 2013 [cited by applicant]
WO WO2014069227A1 · 2014 [cited by applicant]
WO WO2014129384A1 · 2014 [cited by applicant]
Haviv et al. (Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8, 11,13-tetraenoic acid analogs. Journal of Medicinal Chemistry vol. 30 Issue: 2 pp. 254-263 Journal; Comparative Study; … [cited by examiner]
Herrmann et al. (“Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.” Arthritis & Rheumatism 41.7 (1998): 1241-1250. [cited by examiner]
Peng et al. (Regulatory Mechanism of M1/M2 Macrophage Polarization in the Development of Autoimmune Diseases. Mediators Inflamm. Jun. 8, 2023;2023:8821610. doi: 10.1155/2023/8821610. PMID: 37332618; PMCID: PMC10270764. [cited by examiner]
Boddu et al., “Anti-inflammatory effects of a novel ricinoleic acid poloxamer gel system for transdermal delivery,” [cited by applicant]
Cipollina et al., “Cyclooxygenase-2 Generates Anti-inflammatory Omega-3 fatty acid Derivatives in Activated Macrophages,” [cited by applicant]
Haas et al., “Simplifying biodiesel production: The direct or in situ transesterification of algal biomass,” [cited by applicant]
Kim et al., “9-oxo-10(E), 12(E)-octadecadienoic acid derived from tomato is a potent PPARα agonist to decrease triglyceride accumulation in mouse primary hepatocytes,” [cited by applicant]
Kim et al., “Potent PPARα Activator Derived from Tomato Juice, 13-oxo-9,11-Octadecadienoic Acid, Decreases Plasma and Hepatic Triglyceride in Obese Diabetic Mice,” [cited by applicant]
Kishino et al., “Polyunsaturated fatty acid saturation by gut lactic acid bacteria affecting host lipid composition,” [cited by applicant]
Murakami et al., “New class of linoleic acid metabolites biosynthesized by corn and rice lipoxygenases: Suppression of proinflammatory mediator expression via attenuation of MAPK- and Akt-, but not PPARγ-, dependent pat… [cited by applicant]
Tanabe et al., “Production of unique hydroxy fatty acid using lactic acid bacteria,” [cited by applicant]
Tunaru et al., “Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP [cited by applicant]
Vieira et al., “Effect of ricinoleic acid in acute and subchronic experimental models of inflammation,” [cited by applicant]
China National Intellectual Property Administration, Search Report in Chinese Patent Application No. 20158005505.X (Feb. 15, 2019). [cited by applicant]
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2015/051844 (Apr. 28, 2015). [cited by applicant]
U.S. Appl. No. 15/113,714, filed Jul. 22, 2016. [cited by applicant]
Grechkin et al., “The lipoxygenase pathway in tulip ( [cited by applicant]
Nakajima et al., “Synthesis of 13-Oxo-(Z)-9-octadecenoic Acid and 15-Oxo-(Z)-11-icosenoic Acid, Arrestants of [cited by applicant]
Shiraki et al., “α,β-Unsaturated Ketone Is a Core Moiety of Natural Ligands for Covalent Binding to Peroxisome Proliferator-activated Receptor γ,” [cited by applicant]
Belarbi et al., “TNF-α Protein Synthesis Inhibitor Restores Neuronal Function and Reverses Cognitive Deficits Induced by Chronic Neuroinflammation,” [cited by applicant]
De Meyer et al., “Therapeutic Strategies to Deplete Macrophages in Atherosclerotic Plaques,” [cited by applicant]
Galanos et al., “Mechanisms of Endotoxin Shock and Endotoxin Hypersensitivity,” [cited by applicant]
Han et al., “Influence of Mild Hypothermia on Inducible Nitric Oxide Synthase Expression and Reactive Nitrogen Production in Experimental Stroke and Inflammation,” [cited by applicant]
Kasraie et al., “Role of Macrophages in the Pathogenesis of Atopic Dermatitis,” [cited by applicant]
Kinne et al., “Macrophages in Rheumatoid Arthritis,” [cited by applicant]
Li et al., “Microglia-Derived Macrophages in Early Multiple Sclerosis Plaques,” [cited by applicant]
Martin et al., “Resident Macrophages Initiating and Driving Inflammation in a Monosodium Urate Monohydrate Crystal-Induced Murine Peritoneal Model of Acute Gout,” [cited by applicant]
Nikolic-Paterson et al., “The Role of Macrophages in Glomerulonephritis,” [cited by applicant]
Sugimoto et al., “Non-targeted Metabolite Profiling in Activated Macrophage Secretion,” [cited by applicant]
Watanabe et al., “Hepatocellular Oxidative DNA Injury Induced by Macrophage-Derived Nitric Oxide,” [cited by applicant]
Arora et al., “The ATP-Binding Cassette Gene ABCF1 Functions as an E2 Ubiquitin-Conjugating Enzyme Controlling Macrophage Polarization to Dampen Lethal Septic Shock,” [cited by applicant]
Lin et al., “Stefin B alleviates the gouty arthritis in mice by inducing the M2 polarization of macrophages,” [cited by applicant]
Weng et al., “Phenotypic Screening-Based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis,” [cited by applicant]
Wu et al., “Akt2 Affects Periodontal Inflammation via Altering the M1/M2 Ratio,” [cited by applicant]
Yao et al., “Microglial polarization: novel therapeutic mechanism against Alzheimer's disease,” [cited by applicant]
Zheng et al., “Exosomes from LPS-stimulated macrophages induce neuroprotection and functional improvement after ischemic stroke by modulating microglial polarization,” [cited by applicant]